We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $931M
1-Year Est. Return 41.63%
This Fund
S&P 500
This Quarter Est. Return
+31.31%
1 Year Est. Return
+41.63%
3 Year Est. Return
+181.18%
5 Year Est. Return
+113.34%
10 Year Est. Return
+1,823.73%
AUM
$2.59B
AUM Growth
+$94.3M
Cap. Flow
-$53.2M
Cap. Flow %
-2.05%
Top 10 Hldgs %
60.43%
Holding
115
New
13
Increased
19
Reduced
20
Closed
19

Top Buys

Rank Stock Value
1
BNTX icon
BioNTech
BNTX
+$58.9M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$29.9M
3
PYPL icon
PayPal
PYPL
+$20.8M
4
ARGX icon
argenx
ARGX
+$20.3M
5
HARP
Harpoon Therapeutics, Inc. Common Stock
HARP
+$12.9M

Top Sells

Rank Stock Value
1
MDCO
Medicines Co
MDCO
+$70M
2
NVDA icon
NVIDIA
NVDA
+$34.8M
3
AVTR icon
Avantor
AVTR
+$19.9M
4
GBT
Global Blood Therapeutics, Inc.
GBT
+$17M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$15.6M

Sector Composition

Rank Sector Weight
1 Healthcare 63.41%
2 Consumer Discretionary 25.71%
3 Miscellaneous 7.39%
4 Communication Services 1.46%
5 Technology 1.19%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
WW
1
DELISTED
WW International
WW
$566M 21.87%
14,818,300
– –
LXRX icon
2
Lexicon Pharmaceuticals
LXRX
$881M
$250M 9.66%
60,240,864
– –
ALNY icon
3
Alnylam Pharmaceuticals
ALNY
$33.5B
$115M 4.45%
1,000,000
+300,000
+43% +$29.9M
ONC
4
BeOne Medicines Ltd
ONC
$39.2B
$106M 4.1%
640,000
-10,000
-2% -$1.66M
MS icon
5
CALL
Morgan Stanley
MS
$324B
$102M 3.95%
2,000,000
+500,000
+33% +$23.7M
BABA icon
6
Alibaba
BABA
$272B
$95.4M 3.69%
450,000
– –
MRNA icon
7
Moderna
MRNA
$58.6B
$90.1M 3.48%
4,606,298
– –
BNTX icon
8
BioNTech
BNTX
$24.8B
$89M 3.44%
+2,628,130
New +$58.9M
AVTR icon
9
Avantor
AVTR
$10.3B
$86.2M 3.33%
4,750,000
-1,250,000
-21% -$19.9M
XLRN
10
DELISTED
Acceleron Pharma
XLRN
$63.6M 2.46%
1,200,000
-300,000
-20% -$13.7M
ARGX icon
11
argenx
ARGX
$62B
$56.2M 2.17%
350,000
+150,000
+75% +$20.3M
EPZM
12
DELISTED
Epizyme, Inc
EPZM
$55.4M 2.14%
2,250,000
+750,000
+50% +$11.1M
FATE icon
13
Fate Therapeutics
FATE
$277M
$39.1M 1.51%
2,000,000
– –
Z icon
14
Zillow
Z
$7.46B
$34.5M 1.33%
750,000
+100,000
+15% +$3.73M
SRRK icon
15
Scholar Rock
SRRK
$6.31B
$33.6M 1.3%
2,546,040
+200,000
+9% +$1.92M
BPMC
16
DELISTED
Blueprint Medicines
BPMC
$32M 1.24%
400,000
-200,000
-33% -$15M
MORF
17
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$31.2M 1.21%
1,819,186
– –
FOLD
18
DELISTED
Amicus Therapeutics
FOLD
$29.2M 1.13%
3,000,000
+500,000
+20% +$4.58M
ATRA icon
19
Atara Biotherapeutics
ATRA
$94.2M
$28.8M 1.11%
70,000
+10,000
+17% +$3.45M
AGIO icon
20
Agios Pharmaceuticals
AGIO
$1.98B
$28.6M 1.11%
600,000
+200,000
+50% +$7.56M
RUBY
21
DELISTED
Rubius Therapeutics, Inc
RUBY
$26.9M 1.04%
2,833,791
– –
GOSS icon
22
Gossamer Bio
GOSS
$65.4M
$25.1M 0.97%
20,112
– –
PYPL icon
23
PayPal
PYPL
$46.2B
$21.6M 0.84%
+200,000
New +$20.8M
XNCR icon
24
Xencor
XNCR
$1.82B
$18.9M 0.73%
550,000
+250,000
+83% +$9.13M
TPTX
25
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$18.7M 0.72%
300,000
-100,000
-25% -$4.76M
1
2 3 4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $931M AUM 47.97% 1-Year Est. Return
ACM
Ashe Capital Management Englewood Cliffs, New Jersey $931M AUM 4.95% 1-Year Est. Return
SAM
Sycomore Asset Management Paris, France $932M AUM 51.25% 1-Year Est. Return
NS
Night Squared New York $930M AUM 56.46% 1-Year Est. Return
PA
Planning Alternatives Birmingham, Michigan $933M AUM 28.32% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $933M AUM 56.2% 1-Year Est. Return
CICI
Capital Investment Counsel Inc Raleigh, North Carolina $929M AUM 53.07% 1-Year Est. Return
CAM
Claret Asset Management Montreal, Quebec, Canada $928M AUM 25.4% 1-Year Est. Return

Artal Group's Q4 2019 Portfolio in Review

As of Q4 2019, Artal Group held 115 positions worth $2.59B, up 3.8% from $2.49B the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Artal Group's Q4 2019 filing shows 13 new, 19 increased, 20 reduced and 19 closed positions. Its largest new stake was BioNTech: 2,628,130 shares worth $89M. The largest sale was Medicines Co, an estimated $70M.

By sector, the portfolio is most concentrated in Healthcare at 63% of assets, up from 53% a quarter earlier, followed by Consumer Discretionary and Miscellaneous.

  • Artal Group's largest Q4 2019 buy was BioNTech: 2,628,130 shares worth $89M.
  • Artal Group added most to Alnylam Pharmaceuticals in Q4 2019, an estimated $29.9M increase.
  • Artal Group's biggest Q4 2019 reduction was Avantor, cutting an estimated $19.9M.
  • Artal Group fully exited Medicines Co in Q4 2019, selling an estimated $70M.
  • Artal Group's ten largest holdings make up 60% of its $2.59B portfolio in Q4 2019.
  • Artal Group opened 13 new positions and closed 19 in Q4 2019.
  • Artal Group's portfolio value rose 3.8% quarter-over-quarter to $2.59B.

Based on Artal Group's 13F filing for Q4 2019, filed 13 Feb 2020.